118 related articles for article (PubMed ID: 26500848)
1. A radiolabeled antibody targeting CD123(+) leukemia stem cells - initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML.
Leyton JV; Gao C; Williams B; Keating A; Minden M; Reilly RM
Leuk Res Rep; 2015; 4(2):55-9. PubMed ID: 26500848
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
[TBL] [Abstract][Full Text] [Related]
3. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
[TBL] [Abstract][Full Text] [Related]
4. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
[TBL] [Abstract][Full Text] [Related]
5. Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells.
Gao C; Leyton JV; Schimmer AD; Minden M; Reilly RM
Appl Radiat Isot; 2016 Apr; 110():1-7. PubMed ID: 26748017
[TBL] [Abstract][Full Text] [Related]
6. The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates.
Zereshkian A; Leyton JV; Cai Z; Bergstrom D; Weinfeld M; Reilly RM
Nucl Med Biol; 2014; 41(5):377-83. PubMed ID: 24637100
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
He SZ; Busfield S; Ritchie DS; Hertzberg MS; Durrant S; Lewis ID; Marlton P; McLachlan AJ; Kerridge I; Bradstock KF; Kennedy G; Boyd AW; Yeadon TM; Lopez AF; Ramshaw HS; Iland H; Bamford S; Barnden M; DeWitte M; Basser R; Roberts AW
Leuk Lymphoma; 2015 May; 56(5):1406-15. PubMed ID: 25248882
[TBL] [Abstract][Full Text] [Related]
8. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
9. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
[TBL] [Abstract][Full Text] [Related]
11. Favorable tumor uptake and nuclear transport of Auger electrons by nuclear targeting with 111In-trastuzumab in an intraperitoneal tumor mouse model.
Keiko Li H; Hasegawa S
Nucl Med Commun; 2022 Jul; 43(7):763-769. PubMed ID: 35506286
[TBL] [Abstract][Full Text] [Related]
12. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
[TBL] [Abstract][Full Text] [Related]
13. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model.
Rombouts WJ; Martens AC; Ploemacher RE
Leukemia; 2000 May; 14(5):889-97. PubMed ID: 10803522
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
[TBL] [Abstract][Full Text] [Related]
15. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.
Jordan CT; Upchurch D; Szilvassy SJ; Guzman ML; Howard DS; Pettigrew AL; Meyerrose T; Rossi R; Grimes B; Rizzieri DA; Luger SM; Phillips GL
Leukemia; 2000 Oct; 14(10):1777-84. PubMed ID: 11021753
[TBL] [Abstract][Full Text] [Related]
16. Good engraftment of B-cell precursor ALL in NOD-SCID mice.
Baersch G; Möllers T; Hötte A; Dockhorn-Dworniczak B; Rübe C; Ritter J; Jürgens H; Vormoor J
Klin Padiatr; 1997; 209(4):178-85. PubMed ID: 9293448
[TBL] [Abstract][Full Text] [Related]
17. Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.
Mitchell P; Lee FT; Hall C; Rigopoulos A; Smyth FE; Hekman AM; van Schijndel GM; Powles R; Brechbiel MW; Scott AM
J Nucl Med; 2003 Jul; 44(7):1105-12. PubMed ID: 12843229
[TBL] [Abstract][Full Text] [Related]
18. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].
Wang YC; Feng L; Yin CY; Ma LN; Wei YW; Wang CM; Sheng GY
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):577-82. PubMed ID: 23866283
[TBL] [Abstract][Full Text] [Related]
20. Development of [
Laszlo GS; Orozco JJ; Kehret AR; Lunn MC; Huo J; Hamlin DK; Scott Wilbur D; Dexter SL; Comstock ML; O'Steen S; Sandmaier BM; Green DJ; Walter RB
Leukemia; 2022 Jun; 36(6):1485-1491. PubMed ID: 35474099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
